222 related articles for article (PubMed ID: 21745106)
1. The influence of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on osteoclastogenesis.
Ma R; Morshed S; Latif R; Zaidi M; Davies TF
Thyroid; 2011 Aug; 21(8):897-906. PubMed ID: 21745106
[TBL] [Abstract][Full Text] [Related]
2. Thyroid-stimulating hormone maintains bone mass and strength by suppressing osteoclast differentiation.
Zhang W; Zhang Y; Liu Y; Wang J; Gao L; Yu C; Yan H; Zhao J; Xu J
J Biomech; 2014 Apr; 47(6):1307-14. PubMed ID: 24629929
[TBL] [Abstract][Full Text] [Related]
3. TNFalpha mediates the skeletal effects of thyroid-stimulating hormone.
Hase H; Ando T; Eldeiry L; Brebene A; Peng Y; Liu L; Amano H; Davies TF; Sun L; Zaidi M; Abe E
Proc Natl Acad Sci U S A; 2006 Aug; 103(34):12849-54. PubMed ID: 16908863
[TBL] [Abstract][Full Text] [Related]
4. Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption.
Michael H; Härkönen PL; Väänänen HK; Hentunen TA
J Bone Miner Res; 2005 Dec; 20(12):2224-32. PubMed ID: 16294275
[TBL] [Abstract][Full Text] [Related]
5. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
6. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
7. Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors.
Chikazu D; Katagiri M; Ogasawara T; Ogata N; Shimoaka T; Takato T; Nakamura K; Kawaguchi H
J Bone Miner Res; 2001 Nov; 16(11):2074-81. PubMed ID: 11697804
[TBL] [Abstract][Full Text] [Related]
8. High extracellular Ca2+ alone stimulates osteoclast formation but inhibits in the presence of other osteoclastogenic factors.
Shin MM; Kim YH; Kim SN; Kim GS; Baek JH
Exp Mol Med; 2003 Jun; 35(3):167-74. PubMed ID: 12858015
[TBL] [Abstract][Full Text] [Related]
9. Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis.
Tsurukai T; Udagawa N; Matsuzaki K; Takahashi N; Suda T
J Bone Miner Metab; 2000; 18(4):177-84. PubMed ID: 10874596
[TBL] [Abstract][Full Text] [Related]
10. A lack of thyroid hormones rather than excess thyrotropin causes abnormal skeletal development in hypothyroidism.
Bassett JH; Williams AJ; Murphy E; Boyde A; Howell PG; Swinhoe R; Archanco M; Flamant F; Samarut J; Costagliola S; Vassart G; Weiss RE; Refetoff S; Williams GR
Mol Endocrinol; 2008 Feb; 22(2):501-12. PubMed ID: 17932107
[TBL] [Abstract][Full Text] [Related]
11. TSH is a negative regulator of skeletal remodeling.
Abe E; Marians RC; Yu W; Wu XB; Ando T; Li Y; Iqbal J; Eldeiry L; Rajendren G; Blair HC; Davies TF; Zaidi M
Cell; 2003 Oct; 115(2):151-62. PubMed ID: 14567913
[TBL] [Abstract][Full Text] [Related]
12. Osteoprotegerin influences the bone resorption activity of osteoclasts.
Fu YX; Gu JH; Zhang YR; Tong XS; Zhao HY; Yuan Y; Liu XZ; Bian JC; Liu ZP
Int J Mol Med; 2013 Jun; 31(6):1411-7. PubMed ID: 23563320
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.
Kobayashi K; Takahashi N; Jimi E; Udagawa N; Takami M; Kotake S; Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Morinaga T; Higashio K; Martin TJ; Suda T
J Exp Med; 2000 Jan; 191(2):275-86. PubMed ID: 10637272
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway.
Palmqvist P; Lundberg P; Persson E; Johansson A; Lundgren I; Lie A; Conaway HH; Lerner UH
J Biol Chem; 2006 Feb; 281(5):2414-29. PubMed ID: 16251181
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.
Swanson C; Lorentzon M; Conaway HH; Lerner UH
Endocrinology; 2006 Jul; 147(7):3613-22. PubMed ID: 16614077
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.
Shalhoub V; Faust J; Boyle WJ; Dunstan CR; Kelley M; Kaufman S; Scully S; Van G; Lacey DL
J Cell Biochem; 1999 Feb; 72(2):251-61. PubMed ID: 10022507
[TBL] [Abstract][Full Text] [Related]
17. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
[TBL] [Abstract][Full Text] [Related]
18. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis.
Hofbauer LC; Gori F; Riggs BL; Lacey DL; Dunstan CR; Spelsberg TC; Khosla S
Endocrinology; 1999 Oct; 140(10):4382-9. PubMed ID: 10499489
[TBL] [Abstract][Full Text] [Related]
19. Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities.
Wittrant Y; Theoleyre S; Couillaud S; Dunstan C; Heymann D; Rédini F
Exp Cell Res; 2004 Feb; 293(2):292-301. PubMed ID: 14729467
[TBL] [Abstract][Full Text] [Related]
20. Interaction of thyroid-stimulating antibody with Graves' thyroid-stimulating hormone-binding antibody.
Ochi Y; Kajita Y; Hamazu M; Nagata A
Horm Res; 2003; 59(5):222-8. PubMed ID: 12714785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
